Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
Publication
, Journal Article
Wyatt, CM
Published in: Kidney Int
January 2016
The widely used antiretroviral agent tenofovir disoproxil fumarate has been associated with proximal tubular injury and decreased glomerular filtration rate in HIV-infected individuals. Phase 3 trials of a new prodrug, tenofovir alafenamide, suggest a lower potential for kidney injury.
Duke Scholars
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
January 2016
Volume
89
Issue
1
Start / End Page
5 / 6
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tenofovir
- Prodrugs
- Kidney Tubules, Proximal
- Humans
- Glomerular Filtration Rate
- Drug Combinations
- Drug Approval
- Creatinine
- Clinical Trials, Phase III as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Wyatt, C. M. (2016). Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? Kidney Int, 89(1), 5–6. https://doi.org/10.1016/j.kint.2015.11.014
Wyatt, Christina M. “Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?” Kidney Int 89, no. 1 (January 2016): 5–6. https://doi.org/10.1016/j.kint.2015.11.014.
Wyatt CM. Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? Kidney Int. 2016 Jan;89(1):5–6.
Wyatt, Christina M. “Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?” Kidney Int, vol. 89, no. 1, Jan. 2016, pp. 5–6. Pubmed, doi:10.1016/j.kint.2015.11.014.
Wyatt CM. Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? Kidney Int. 2016 Jan;89(1):5–6.
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
January 2016
Volume
89
Issue
1
Start / End Page
5 / 6
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tenofovir
- Prodrugs
- Kidney Tubules, Proximal
- Humans
- Glomerular Filtration Rate
- Drug Combinations
- Drug Approval
- Creatinine
- Clinical Trials, Phase III as Topic